Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Folia Histochemica et Cytobiologica
MENU
Shortcuts Submit an article Author Guidelines Ahead of Print Reviewers 2023 Editorial Board

open access

Vol 50, No 2 (2012)
Review paper
Submitted: 2012-07-04
Accepted: 2012-07-04
Published online: 2012-07-05
View PDF Download PDF file
Get Citation

The role of leukotrienes in the pathogenesis of systemic sclerosis

Sylwia Chwieśko-Minarowska, Krzysztof Kowal, Marek Bielecki, Otylia Kowal-Bielecka
DOI: 10.5603/FHC.2012.0027
·
Folia Histochem Cytobiol 2012;50(2):180-185.

open access

Vol 50, No 2 (2012)
REVIEW
Submitted: 2012-07-04
Accepted: 2012-07-04
Published online: 2012-07-05

Abstract

Systemic sclerosis (SSc, scleroderma) is an autoimmune disease characterized by widespread vascular injury and progressive fibrosis of the skin and internal organs. SSc-related involvement of the lungs, heart, kidneys and/or the gastrointestinal system accounts for the increased mortality of scleroderma patients. Despite the progress which has recently been made in this field, the treatment of SSc is still unsatisfactory due to the low efficacy and/or high toxicity of available therapies. Leukotrienes are a family of lipid mediators synthesized from arachidonic acid in a process mediated by 5-lipoxygenase; they include leukotriene B4 and a group of cysteinyl leukotrienes: C4, D4, and E4. Leukotrienes play an important role in the regulation of all the processes vital to the pathogenesis of SSc, namely inflammation, vascular function and connective tissue remodeling. The available data suggests that an excessive synthesis of leukotrienes may contribute to the development and progression of SSc. Accordingly, blockade of leukotriene pathways appears to be a new, promising target for the  reatment of SSc.

Abstract

Systemic sclerosis (SSc, scleroderma) is an autoimmune disease characterized by widespread vascular injury and progressive fibrosis of the skin and internal organs. SSc-related involvement of the lungs, heart, kidneys and/or the gastrointestinal system accounts for the increased mortality of scleroderma patients. Despite the progress which has recently been made in this field, the treatment of SSc is still unsatisfactory due to the low efficacy and/or high toxicity of available therapies. Leukotrienes are a family of lipid mediators synthesized from arachidonic acid in a process mediated by 5-lipoxygenase; they include leukotriene B4 and a group of cysteinyl leukotrienes: C4, D4, and E4. Leukotrienes play an important role in the regulation of all the processes vital to the pathogenesis of SSc, namely inflammation, vascular function and connective tissue remodeling. The available data suggests that an excessive synthesis of leukotrienes may contribute to the development and progression of SSc. Accordingly, blockade of leukotriene pathways appears to be a new, promising target for the  reatment of SSc.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

leukotrienes; scleroderma; SSc-related insterstitial lung disease

About this article
Title

The role of leukotrienes in the pathogenesis of systemic sclerosis

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 50, No 2 (2012)

Article type

Review paper

Pages

180-185

Published online

2012-07-05

Page views

2427

Article views/downloads

2486

DOI

10.5603/FHC.2012.0027

Bibliographic record

Folia Histochem Cytobiol 2012;50(2):180-185.

Keywords

leukotrienes
scleroderma
SSc-related insterstitial lung disease

Authors

Sylwia Chwieśko-Minarowska
Krzysztof Kowal
Marek Bielecki
Otylia Kowal-Bielecka

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl